Back to top
more

Halozyme Therapeutics (HALO)

(Real Time Quote from BATS)

$62.86 USD

62.86
3,198,935

+2.05 (3.37%)

Updated Aug 6, 2025 02:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Halozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 16.84% and 10.82%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is Invesco S&P MidCap 400 GARP ETF (GRPM) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for GRPM

Zacks Equity Research

Techne (TECH) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Why Is Acadia (ACAD) Down 11.1% Since Last Earnings Report?

by Zacks Equity Research

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Myriad (MYGN) Down 17.1% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy?

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Is Brookdale Senior Living (BKD) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Brookdale Senior Living (BKD) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.

Zacks Equity Research

HALO vs. AMGN: Which Stock Is the Better Value Option?

by Zacks Equity Research

HALO vs. AMGN: Which Stock Is the Better Value Option?

Zacks Equity Research

Should Invesco S&P MidCap 400 GARP ETF (GRPM) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for GRPM

Zacks Equity Research

Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Is Invesco S&P MidCap 400 GARP ETF (GRPM) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for GRPM

Zacks Equity Research

Is Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think "Yes"

by Zacks Equity Research

Halozyme Therapeutics (HALO) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Equity Research

Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

HALO's Q4 Earnings Beat, Higher Royalties Drive Revenue Growth

by Zacks Equity Research

Halozyme reports better-than-expected fourth-quarter 2024 results. The company maintains revenue guidance for 2025.

Zacks Equity Research

Halozyme Therapeutics (HALO) Reports Q4 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

While the top- and bottom-line numbers for Halozyme Therapeutics (HALO) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Halozyme Therapeutics (HALO) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 8.62% and 4.93%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Ahan Chakraborty headshot

Will These 5 Biotech Stocks Surpass Q4 Earnings Forecast?

by Ahan Chakraborty

Let's look at five biotech and drug companies, AXSM, HALO, FOLD, BMRN and INSM, slated to release their fourth-quarter 2024 results this week.

Zacks Equity Research

HALO Gears Up to Report Q4 Earnings: Here's What You Should Know

by Zacks Equity Research

Halozyme's fourth-quarter earnings are likely to have gained from higher royalty payments and revenues from collaboration agreements for its Enhanze technology.

Zacks Equity Research

Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Here's How Much You'd Have If You Invested $1000 in Halozyme Therapeutics a Decade Ago

by Zacks Equity Research

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.